Shengshi Taikang: Approaching innovation in pharmaceuticals for the public with the mindset of a long, determined journey.

　　On November 21, the fourth stop of the company visit program—organized under the guidance of the Organization Department of the CPC Committee of Suzhou Industrial Park, hosted by the Suzhou Industrial Park Enterprise Development Service Center, and undertaken by the Suzhou Industrial Park Talent Innovation & Entrepreneurship Promotion Association—was successfully held. Dr. Yu Qiang, founder of Shengshi Taike and chairman of the Suzhou Industrial Park Talent Innovation & Entrepreneurship Promotion Association, joined over 10 entrepreneurs and executives on-site to share the "bittersweet experiences" in the innovative pharmaceutical sector.

　　Founded in 2010 and rooted in Suzhou Industrial Park, Shengshi Taikang is a biotechnology company dedicated to the research and development of small-molecule drugs in the areas of blood sugar control, cancer therapy, and rare diseases. To date, the company has secured 6 clinical approvals and filed 30 patent applications, including 14 granted invention patents—more than half of which are protected globally. As Shengshi Taikang continues to establish itself in China, it’s firmly on its journey to make a global impact.

　　Since its establishment, the company has built a robust pipeline of innovative Class 1 drugs. Among them, Senglitin phosphate—a novel DPP-4 inhibitor developed entirely in-house—is currently in Phase III clinical trials, with completion expected by mid-2022. As Dr. Yu Qiang often puts it with his trademark vivid analogy: "Without scaling snowy mountains or wading through grasslands, there’s no way to liberate all of China." This milestone signals that Shengshi Taikang’s first-in-class innovative drug will soon enter the regulatory approval process next year, having already achieved its primary clinical efficacy endpoint. The anticipated approval of Senglitin phosphate is poised to fill a critical gap in the domestic market for DPP-4 inhibitors—since all currently approved options are imported products—and is set to unlock significant growth potential. When Dr. Yu Qiang modestly described this achievement as "the first step of a long and arduous journey," the audience erupted into spontaneous, heartfelt applause. Industry peers deeply understood that behind these seemingly effortless words lay years of unwavering dedication and relentless perseverance.

　　"Our project deadline is always yesterday!"—this signature "catchphrase" from Shengshi Taikang underscores their rigorous approach to project management. Despite the company’s growth over the years, it has maintained remarkable talent stability: not a single director-level employee or higher has left for another organization. In an era marked by intense competition for top talent, this achievement is truly exceptional—and it also subtly highlights the company’s compelling culture and strong internal drive.

　　During the subsequent discussion, the visiting delegation engaged in a lively exchange on topics such as industry trends, business models, and innovative strategies for expanding overseas. Wang Kuifeng, CEO of Qinhao Pharmaceutical, Jiang Gaoxi, CEO of Waines Bio, along with colleagues from Xukang Medical and Ganxin Microsystem, shared their insights and posed thought-provoking questions, fostering stronger connections and opening up new avenues for collaboration.

　　(By "Suzhou Industrial Park Smart Talent")